Clinical trial · Observational
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
A Prospective Study on Investigating the Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
NCT06597539CI-TRIAL-00083613recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatobiliary Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Diagnosis of advanced hepatobiliary malignancies
- description
- Patients diagnosis of advanced hepatobiliary malignancies require immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
Primary outcomes (3)
- measure
- Evaluation the responses to immunotherapy of advanced hepatobiliary malignancy
- timeFrame
- up to 9 weeks
- description
- The value of 68Ga-grazytracer PET in monitoring responses to immunotherapy of advanced hepatobiliary malignancy
- measure
- Standardized uptake value(SUV)
- timeFrame
- up to 9 weeks
- description
- SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions
- measure
- Target-to-background ratio(TBR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines 2. Signed and dated informed consent form 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process 4. aged 18-75 years old 5. The patient is in good general condition with an expected survival of \> 6 months Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol/L on the day of the trial 4. Pregnant women and women who may be pregnant, women who are breastfeeding. 5. Non-compliant person
References
Publications (0)
Data not yet available
No reference posted for this study.